
Moderna Jumps 7.5% After Disclosing Hantavirus Vaccine Development Amid Cruise Ship Outbreak
Shares of Moderna surged 7.5% on Monday after the biotech company disclosed that it had been developing a hantavirus vaccine ahead of the outbreak aboard the MV Hondius cruise ship. The single-day move stood out against an otherwise quiet trading session and gave investors fresh evidence that Moderna’s pipeline extends beyond the COVID-19 franchise that has defined its public profile for the past five years. The move came as two American patients exposed to hantavirus aboard the MV Hondius were transferred Monday to Emory University Hospital in Atlanta for treatment at the hospital’s Serious Communicable Diseases Unit. Sixteen additional Americans from the same vessel were evacuated to the University of Nebraska Medical Center in Omaha, the country’s only national quarantine unit. For Moderna, the disclosure landed at a particularly useful moment. Biotech stocks have come under sustained pressure in recent quarters, weighed down by GLP-1 competition, broader healthcare cost concerns, and questions about post-pandemic vaccine demand. Monday’s rally suggests investors are reassessing the company’s broader infectious disease pipeline, even if the immediate commercial implications of hantavirus work remain narrow. Why Hantavirus Matters Now Hantavirus is a category of rare viruses that, in most cases, spread to humans through inhalation of













































